Objectives3,4-methylenedioxymethamphetamine (MDMA) and psilocybin are being investigated as potential treatments for psychiatric disorders and have received increasing regulatory and media attention due to the methodological complexities and societal context of psychedelic substances. Therefore, we assessed the consistency of protocol registration and advers...
The principal investigator for this study plans to build upon the psilocybin-assisted therapy intervention used in prior completed trials to conduct an open-label trial of two psilocybin administration sessions combined with psychotherapy to investigate the safety, tolerability, and clinical efficacy of psilocybin-assisted therapy for the treatment of PTSD i...
ClinicalTrials.gov2026-01-21Baylor College of Medicine
The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some preclinical data suggest these putative benefits derive from direct analgesic effects; however, this possibility has not been comprehensively tested in preclinical models. Here, we evaluated the analgesic properties of a single exposure to psilocybi...
The green synthesis of nanomaterials has emerged as a viable alternative to traditional techniques that reduce environmental risks and the production of harmful byproducts. In this work, biomaterial derived from wild mushrooms was used to synthesize psilocybin-derived carbon nanosheets (P-CNSs). The bioactive substance psilocybin serves as a sustainable prec...
BackgroundSelf-transcendent and mystical experiences may be key mechanisms underlying psychedelics' therapeutic effects, yet how these experiences differ across substances remains unclear. This study compared mystical and self-transcendent experiences across psilocybin, 3,4-Methylenedioxymethamphetamine (MDMA), and cannabis in a diverse, community-based samp...
Unknown journal2026-01-20Chwyl C, Spata A, Lucas W, Luoma JB.
Europe PMCPublishedpsilocybinMechanism of ActionPersonality ChangeEmotional ProcessingSpiritualityMystical ExperienceAdolescentsClinical TrialHumansCannabis
ObjectiveThis study was undertaken to identify gaps in cluster headache management, highlight patient-prioritized research needs, and assess patient interest in, and preferences for, clinical trial participation.BackgroundMany people with cluster headache still lack effective treatment options to control or prevent attacks. There is a critical need for more ...
Psilocybin is a naturally occurring psychedelic compound with potential antidepressant effects. Although it has long been used by humans, primarily for recreational purposes, the molecular mechanisms underlying its actions remain incompletely understood. Here, we examined the acute effects of psilocin, the active metabolite of psilocybin, on excitatory neuro...
Unknown journal2026-01-20Domi A, Lucente E, Cadeddu D, Bengtsson N, Smedler E, Adermark L.
Europe PMCPublishedpsilocybinpsilocinDepressionNeuroplasticityMechanism of ActionReceptor PharmacologyAnimal StudyDrug InteractionsAnimal StudyPrefrontal CortexAnimals
INTRODUCTION: Psilocybin, a classic serotonergic psychedelic, has antidepressant, anxiolytic, anti-inflammatory, and analgesic properties. However, the immunomodulatory effects of psilocybin within the central nervous system, particularly on microglial activation, remain poorly understood. Therefore, this study aimed to investigate the effects of psilocybin ...
Psilocybin has been reported to decrease depression symptoms among individuals with bipolar disorder (BD), but has also been associated with reports of mania, psychosis and increased depression. With increasing recreational use of psilocybin, and the potential for psilocybin to be used as a treatment for depression, a better understanding of the risks and be...
Panaeolus sensu lato is a group of hallucinogenic mushrooms commonly found on dung, in pasture areas, grasslands, and forests. Previous studies indicated that the Panaeolus s.l. clade (panaeo-clade) could be ranked as a family (Galeropsidaceae), pending further evidence. In this study, based on phylogenomic, multigene phylogenetic, molecular clock, and morph...
BackgroundPsilocybin-assisted psychotherapy shows promise in alcohol use disorder (AUD), but therapeutic mechanisms remain poorly understood. Previous qualitative studies have described potential processes such as gaining insights, altered self-perception, connectedness, and changes in coping, yet findings remain limited and inconsistent in AUD, and little i...
Unknown journal2026-01-18Garcia Garcia M, Belahda D, Graux C, Serrand C, Igounenc N, Sergent F, Mura T, Luquiens A.
Europe PMCPublishedpsilocybinDepressionAddictionChronic PainMechanism of ActionBiomarkersEmotional ProcessingRandomized Controlled TrialRandomized Controlled TrialHumansAlcoholism
Background: Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this study, we designed and tested a group model of psilocybin therapy for people with metastatic cancer and cancer-related anxiety and depression. Method: Eligibility criteria included metastatic cancer, moderate-to-...
Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric conditions, despite potentially serious drug-drug interactions and associated dietary tyramine restrictions. However, they are rarely prescribed in patients with comorbid substance use disorders (SUDs) due to concerns a...
Psilocybin-assisted therapies are increasingly studied for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD), and methodological rigor requires both pharmacological evaluation and consistent reporting of non-pharmacological variables that influence therapeutic outcomes. To address this need, the ReSPCT (Reporting of Setting in Psychede...
Floatation-REST (Reduced Environmental Stimulation Therapy) systematically alters sensory and bodily input by combining neutral buoyancy, thermal and proprioceptive neutrality, attenuation of exteroceptive stimulation, and enhancement of cardiorespiratory signaling to the brain. Here we examined whether this non-pharmacological sensory perturbation induces a...
Background: Obsessive-compulsive disorder (OCD) affects 2-3% of the population worldwide. 40-60% of patients do not respond to first-line interventions. We evaluated the efficacy and safety of a single dose of psilocybin in patients with treatment-resistant OCD. Methods: In this phase 2, randomized, double-blind trial, we randomly assigned 28 adults with tre...
Floatation-REST (Reduced Environmental Stimulation Therapy) systematically alters sensory and bodily input by combining neutral buoyancy, thermal and proprioceptive neutrality, attenuation of exteroceptive stimulation, and enhancement of cardiorespiratory signaling to the brain. Here we examined whether this non-pharmacological sensory perturbation induces a...
PsyArXiv2026-01-14Authors unavailable
PsyArXivPREPRINT (not peer reviewed)psilocybinDepressionAnxietyMechanism of ActionConsciousnessSpiritualityRandomized Controlled TrialRandomized Controlled TrialNeuroscienceSocial and Behavioral Sciences
The serotonergic psychedelic, psilocybin, shows potential for rapid and sustained antidepressant effects but the underlying mechanisms remain unknown. Using a chronic interferon-alpha-induced rat model of depression, we show acute psilocybin (0.3 mg/kg) reverses impaired reward-induced biases within 24hrs, with effects enduring for at least 7 days. This sugg...
Background: Obsessive-compulsive disorder (OCD) affects 2-3% of the population worldwide. 40-60% of patients do not respond to first-line interventions. We evaluated the efficacy and safety of a single dose of psilocybin in patients with treatment-resistant OCD. Methods: In this phase 2, randomized, double-blind trial, we randomly assigned 28 adults with tre...
